Suggested Topics within your search.
Suggested Topics within your search.
- Rhetoric 5
- English language 4
- Grammar 4
- Attitude to Health 3
- Behavioral Medicine 2
- Handbooks, manuals, etc 2
- Health behavior 2
- Psychology 2
- Animals 1
- Brothers and sisters 1
- Business communication 1
- Business writing 1
- Care 1
- Case studies 1
- Child development 1
- Child rearing 1
- Communication in organizations 1
- Dialectical materialism 1
- Education 1
- Elias (Fictitious character) 1
- English 1
- Examinations, questions, etc 1
- Fantasy 1
- Fiction 1
- Fugitives from justice 1
- Habitat (Ecology) 1
- Health 1
- Infants 1
- Laia (Fictitious character) 1
- Mass media 1
-
3181
Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
Published 2025-01-01Subjects: Get full text
Article -
3182
Assessing the Different Nanoparticle-Reinforced Bonding Agents on the Shear Bond Strength of Orthodontic Brackets
Published 2024-12-01Subjects: Get full text
Article -
3183
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
Published 2025-02-01Subjects: Get full text
Article -
3184
The Poisson Extension of the Unrelated Question Model: Improving Surveys With Time-Constrained Questions on Sensitive Topics
Published 2024-04-01Subjects: “…Randomized Response Technique…”
Get full text
Article -
3185
Reseña de Libros: GUSINDE HENTSCHEL, Martin; Diarios de viaje de investigación a Tierra del Fuego (1918-1920), Penguin Random House, Santiago de Chile, 2022, 136 pp. Traducción de Marisol Palma Behnke.
Published 2024-10-01“…Reseña de Libros: GUSINDE HENTSCHEL, Martin; Diarios de viaje de investigación a Tierra del Fuego (1918-1920), Penguin Random House, Santiago de Chile, 2022, 136 pp. Traducción de Marisol Palma Behnke.…”
Get full text
Article -
3186
Bringing Intelligence to the Edge for Structural Health Monitoring: The Case Study of the Z24 Bridge
Published 2024-01-01Subjects: Get full text
Article -
3187
-
3188
Application of ensemble learning techniques to model the atmospheric concentration of SO2
Published 2019-07-01Subjects: Get full text
Article -
3189
A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
Published 2025-04-01“…Methods: In this phase III, double-blind, multinational, randomized trial (NCT03583333), adults with HABP/VABP were randomized 1:1 to receive intravenous IMI/REL (500 mg/250 mg) or piperacillin/tazobactam (PIP/TAZ; 4000 mg/500 mg) every 6 h for 7-14 days. …”
Get full text
Article -
3190
Efficacy and safety of glycyrrhizic acid and essential phospholipids (Phosphogliv) combination for alcoholic liver disease: results of the double-blind randomized placebo-controlled multicenter post-registration (phase IV) clinical trial «Jaguar» (PHG-M2/P03-12)
Published 2018-08-01“…The original study included overall 120 patients with ALD, who were randomized in two identical groups. The patients of the main group (group A) received 2 courses of therapy: the first - Phosphogliv 5 mg/day as intravenous bolus injection for 2 wks, followed by the oral intake of 2 capsules t.i.d. for 10 wks (the total treatment duration was 24 wks). …”
Get full text
Article -
3191
Acupuncture and Kinesitherapy Improve Physical Activity More than Kinesitherapy Alone in Patients with Acute Decompensated Chronic Heart Failure with Reduced Ejection Fraction Who Are Already on Optimal Drug Therapy: A Randomized, Sham-Controlled, Double-Blind Clinical Study
Published 2025-01-01“…<b>Methods</b>: A prospective, sham-procedure-controlled, double-blind, randomized clinical trial with three patient groups was conducted. …”
Get full text
Article -
3192
The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study
Published 2025-01-01“…This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone. Method: This randomized, double-blind, parallel-controlled Phase Ib clinical study was conducted in healthy Chinese population to evaluate the safety, pharmacokinetics, and neutralizing activity of rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines, and to compare the neutralizing activity of rhRIG + vaccine with that of HRIG + vaccine and vaccine alone. 72 healthy participants divided into 6 groups of 12 individuals. …”
Get full text
Article -
3193
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study
Published 2025-12-01“…Six hundred children were randomly assigned to six study arms (1:1:1:1:1:1). …”
Get full text
Article -
3194
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Published 2025-12-01“…Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).Methods In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks. …”
Get full text
Article -
3195
Assessment, Decision, Adaptation, Production, Topical Experts-Integration, Training, and Testing (ADAPT-ITT) Framework to Tailor Evidence-Based Posttraumatic Stress Disorder Treatment for People With HIV to Enhance Engagement and Adherence: Qualitative Results from a Feasibility Randomized Controlled Trial
Published 2025-01-01Get full text
Article -
3196
Machine learning-based study of hardness in polypropylene/carbon nanotube and low-density polyethylene/carbon nanotube composites
Published 2025-01-01Subjects: Get full text
Article -
3197
-
3198
-
3199
-
3200